Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Prostatic Intraepithelial Neoplasia 1Male Urogenital Diseases 1

Interventions

Cyclophosphamide 548pembrolizumab 385Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Has results × Lycopene × Clear all
NCT01882985 2021-01-05

Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients

University of California, Irvine

Phase 2 Completed
14 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT01443026 2019-11-19

The Effects of Lycopene on High Risk Prostatic Tissue

University of Illinois at Chicago

Phase 2 Completed
66 enrolled 8 charts
Genitourinary

Prostatic Neoplasms, Prostatic Intraepithelial Neoplasia, Male Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡